MedTrace Logo

JC-Virus (JCV) Antibody Program

NCT01070823 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1096

Last updated 2016-10-05

No results posted yet for this study

Summary

The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment. Secondary objectives are to analytically validate the anti-JCV antibody assay in a plasma matrix and to determine changes in anti-JCV antibody status over time.

Conditions

Interventions

DRUG

Tysabri® (natalizumab)

Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program

Sponsors & Collaborators

  • United BioSource, LLC

    collaborator INDUSTRY

  • Elan Pharmaceuticals

    collaborator INDUSTRY

  • Biogen

    lead INDUSTRY

Principal Investigators

  • Medical Director · Biogen

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01070823 on ClinicalTrials.gov